Bio-Techne
$72.40Change from previous close: 0.00%
At a glance
- Revenue growth
- −0.38%
- FY to Jun 2026 vs FY to Jun 2025
- Net income growth
- +147.77%
- FY to Jun 2026 vs FY to Jun 2025
- Net margin
- 15.0%
- FY to Jun 2025: 6.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 95.4 | 86.7 | 82.4 | 27.6 | 98.2 | — |
| Depreciation and amortization | 24.1 | 24.2 | 24.7 | 24.3 | 27.1 | — |
| Capital expenditure | -8.5 | -9.1 | -5.9 | -5.4 | -4.9 | — |
| Investing cash flow | -7.1 | -5.8 | -5.9 | 0.6 | 0.4 | — |
| Financing cash flow | -33.2 | -42.7 | -49.0 | -44.2 | -90.5 | — |
| Dividends paid | -12.5 | -12.5 | -12.5 | -12.4 | -12.4 | — |
| Share repurchases | -41.7 | 0.0 | 0.0 | -0.0 | -100 | — |
| Debt issued | 0.0 | — | — | — | 66.0 | 38.0 |
| Debt repaid | 0.0 | -60.0 | -40.0 | -46.0 | -50.0 | — |
| Effect of exchange rates | -0.3 | -1.2 | 0.4 | -1.2 | 13.4 | — |
| Net change in cash | 55.2 | 38.1 | 27.5 | -16.0 | 8.2 | — |
| Free cash flow | 86.9 | 77.6 | 76.5 | 22.2 | 93.3 | — |